Synlogic (SYBX) Reports Q3 Loss of $0.43, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Synlogic Reports Third Quarter 2018 Financial Results and Provides Program Updates
November 13, 2018 4:05 PM ESTAdvancement of SYNB1891, the first Synthetic Biotic immuno-oncology candidate to enable Investigational New Drug Application (IND) filing in 2H 2019
Ongoing clinical trials of SYNB1020 and SYNB1618 in patients with data expected in 2019
Management to host conference call and webcast at 5:00 pm ET today
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Synlogic, Inc. (Nasdaq: SYBX), a... More
